nach oben

Neurological Sciences

Erschienen in:

01.11.2018 | Original Article

Analysis of the clinical features of early Parkinson’s disease with comparatively integrated intestinal function

verfasst von: Xiaoxue Guan, Yuchan Wang, Qun Li, Ming Wei, Lili Chen, Oumei Cheng

Erschienen in: Neurological Sciences | Ausgabe 11/2018

Einloggen, um Zugang zu erhalten

Abstract

Objective

Constipation is among the most frequently delineated nonmotor symptoms (NMS) with a high occurrence in Parkinson’s disease (PD). The purpose of our study was to investigate whether PD with comparatively integrated intestinal function (without constipation) in the early stage had different clinical features compared to constipated PD.

Method

We conducted a study of 105 consecutive de novo as well as early treated (treated for shorter than 3 months), aged 50 years or older outpatients. Subjects were administered motor and nonmotor questionnaires as well as constipation associated examinations. Then, we explored the distinctive features of nonconstipated contrasted to constipated PD by using univariate, multiple regression analysis and correlation analysis.

Results

Nonconstipated PD tended to have fewer motor deficits, as well as lower Hoehn and Yahr (H&Y) stage and they mainly presented as tremor-dominant (TD), while constipated group had a higher occurrence of posture instability and gait difficulty (PIGD); nonconstipated patients were inclined to live in urban area, the NMSloads and prevalence of NMS were lower compared to constipated ones. Correlation analysis found a discord between NMSloads and disease severity based on H&Y stage and motor scores in nonconstipated PD.

Conclusions

These results suggest that PD without constipation in early stage may represent a unique clinical phenotype, which may be more benign than PD with constipation.

Chaudhuri KR, Martinez-Martin P, Schapira AH, Stocchi F, Sethi K, Odin P et al (2006) International multicenter pilot study of the first comprehensive self-completed nonmotor symptoms questionnaire for Parkinson’s disease: the NMSQuest study. Mov Disord 21(7):916–923CrossRef

Savica R, Carlin JM, Grossardt BR, Bower JH, Ahlskog JE, Maraganore DM et al (2009) Medical records documentation of constipation preceding Parkinson disease: a case-control study. Neurology 73(21):1752–1758CrossRef

Adams-Carr KL, Bestwick JP, Shribman S, Lees A, Schrag A, Noyce AJ (2016) Constipation preceding Parkinson’s disease: a systematic review and meta-analysis. J Neurol Neurosurg Psychiatry 87(7):710–716CrossRef

Fasano A, Visanji NP, Liu LW, Lang AE, Pfeiffer RF (2015) Gastrointestinal dysfunction in Parkinson’s disease. Lancet Neurol 14(6):625–639CrossRef

Klingelhoefer L, Reichmann H (2015) Pathogenesis of Parkinson disease--the gut-brain axis and environmental factors. Nat Rev Neurol 11(11):625–636CrossRef

Pellegrini C, Antonioli L, Colucci R, Ballabeni V, Barocelli E, Bernardini N et al (2015) Gastric motor dysfunctions in Parkinson’s disease: current pre-clinical evidence. Parkinsonism Relat Disord 21(12):1407–1414CrossRef

Kim JS, Park IS, Park HE, Kim SY, Yun JA, Jung CK et al (2017) α-Synuclein in the colon and premotor markers of Parkinson disease in neurologically normal subjects. Neurol Sci 38(1):171–179CrossRef

Hawkes CH, Del Tredici K, Braak H (2007) Parkinson’s disease: a dual-hit hypothesis. Neuropathol Appl Neurobiol 33(6):599–614CrossRef

Braak H, Rub U, Gai WP, Del Tredici K (2003) Idiopathic Parkinson’s disease: possible routes by which vulnerable neuronal types may be subject to neuroinvasion by an unknown pathogen. J Neural Transm (Vienna) 110(5):517–536CrossRef

10.

Braak H, Del Tredici K, Rub U, de Vos RA, Jansen Steur EN, Braak E (2003) Staging of brain pathology related to sporadic Parkinson’s disease. Neurobiol Aging 24(2):197–211CrossRef

11.

Derkinderen P, Rouaud T, Lebouvier T, Bruley d, Varannes S, Neunlist M, De Giorgio R (2011) Parkinson disease: the enteric nervous system spills its guts. Neurology 77(19):1761–1767CrossRef

12.

Benarroch EE (2007) Enteric nervous system: functional organization and neurologic implications. Neurology 69(20):1953–1957CrossRef

13.

Schapira AHV, Chaudhuri KR, Jenner P (2017) Non-motor features of Parkinson disease. Nat Rev Neurosci 18(7):435–450CrossRef

14.

Kalaitzakis ME, Graeber MB, Gentleman SM, Pearce RK (2008) The dorsal motor nucleus of the vagus is not an obligatory trigger site of Parkinson’s disease: a critical analysis of alpha-synuclein staging. Neuropathol Appl Neurobiol 34(3):284–295CrossRef

15.

Attems J, Jellinger KA (2008) The dorsal motor nucleus of the vagus is not an obligatory trigger site of Parkinson’s disease. Neuropathol Appl Neurobiol 34(4):466–467CrossRef

16.

Annerino DM, Arshad S, Taylor GM, Adler CH, Beach TG, Greene JG (2012) Parkinson’s disease is not associated with gastrointestinal myenteric ganglion neuron loss. Acta Neuropathol 124(5):665–680CrossRef

17.

Pfeiffer RF (2014) Parkinson’s disease and the gut: ‘the wheel is come full circle’. J Parkinson Dis 4(4):577–578

18.

Selikhova M, Williams DR, Kempster PA, Holton JL, Revesz T, Lees AJ (2009) A clinico-pathological study of subtypes in Parkinson’s disease. Brain 132(Pt 11):2947–2957CrossRef

19.

Halliday G, Lees A, Stern M (2011) Milestones in Parkinson’s disease--clinical and pathologic features. Mov Disord 26(6):1015–1021CrossRef

20.

Sauerbier A, Jenner P, Todorova A, Chaudhuri KR (2016) Non motor subtypes and Parkinson’s disease. Parkinsonism Relat Disord 22(Suppl 1):S41–S46CrossRef

21.

Erro R, Vitale C, Amboni M, Picillo M, Moccia M, Longo K et al (2013) The heterogeneity of early Parkinson’s disease: a cluster analysis on newly diagnosed untreated patients. PLoS One 8(8):e70244CrossRef

22.

Zhu L, Liu W, Alkhouri R, Baker RD, Bard JE, Quigley EM et al (2014) Structural changes in the gut microbiome of constipated patients. Physiol Genomics 46(18):679–686CrossRef

23.

Jankovic J, McDermott M, Carter J, Gauthier S, Goetz C, Golbe L et al (1990) Variable expression of Parkinson’s disease: a base-line analysis of the DATATOP cohort. The Parkinson study group. Neurology 40(10):1529–1534CrossRef

24.

Burn DJ, Landau S, Hindle JV, Samuel M, Wilson KC, Hurt CS et al (2012) Parkinson’s disease motor subtypes and mood. Mov Disord 27(3):379–386CrossRef

25.

Thenganatt MA, Jankovic J (2014) Parkinson disease subtypes. JAMA Neurol 71(4):499–504CrossRef

26.

Atac Ucar C, Gokce Cokal B, Unal Artik HA, Inan LE, Yoldas TK (2017) Comparison of neutrophil-lymphocyte ratio (NLR) in Parkinson’s disease subtypes. Neurol Sci 38(2):287–293CrossRef

27.

Hughes AJ, Daniel SE, Kilford L, Lees AJ (1992) Accuracy of clinical diagnosis of idiopathic Parkinson’s disease: a clinico-pathological study of 100 cases. J Neurol Neurosurg Psychiatry 55(3):181–184CrossRef

28.

Pont-Sunyer C, Hotter A, Gaig C, Seppi K, Compta Y, Katzenschlager R et al (2015) The onset of nonmotor symptoms in Parkinson’s disease (the ONSET PD study). Mov Disord 30(2):229–237CrossRef

29.

Reijnders JS, Ehrt U, Lousberg R, Aarsland D, Leentjens AF (2009) The association between motor subtypes and psychopathology in Parkinson’s disease. Parkinsonism Relat Disord 15(5):379–382CrossRef

30.

Rajput AH, Voll A, Rajput ML, Robinson CA, Rajput A (2009) Course in Parkinson disease subtypes: a 39-year clinicopathologic study. Neurology 73(3):206–212CrossRef

31.

Martinez-Martin P, Schapira AH, Stocchi F, Sethi K, Odin P, MacPhee G et al (2007) Prevalence of nonmotor symptoms in Parkinson’s disease in an international setting; study using nonmotor symptoms questionnaire in 545 patients. Mov Disord 22(11):1623–1629CrossRef

32.

Chaudhuri KR, Healy DG, Schapira AH (2006) Non-motor symptoms of Parkinson’s disease: diagnosis and management. Lancet Neurol 5(3):235–245CrossRef

33.

Rodriguez-Violante M, de Sarachaga AJ, Cervantes-Arriaga A, Millan-Cepeda R, Leal-Ortega R, Estrada-Bellmann I et al (2016) Self-perceived pre-motor symptoms load in patients with Parkinson’s disease: a retrospective study. J Parkinson Dis 6(1):183–190CrossRef

34.

Thompson WG, Longstreth GF, Drossman DA, Heaton KW, Irvine EJ, Muller-Lissner SA (1999) Functional bowel disorders and functional abdominal pain. Gut 45(Suppl 2):Ii43–Ii47PubMedPubMedCentral

35.

Stirpe P, Hoffman M, Badiali D, Colosimo C (2016) Constipation: an emerging risk factor for Parkinson’s disease? Eur J Neurol 23:1606–1613CrossRef

36.

Marras C, Chaudhuri KR (2016) Nonmotor features of Parkinson’s disease subtypes. Mov Disord 31(8):1095–1102CrossRef

37.

Eggers C, Pedrosa DJ, Kahraman D, Maier F, Lewis CJ, Fink GR et al (2012) Parkinson subtypes progress differently in clinical course and imaging pattern. PLoS One 7(10):e46813CrossRef

38.

van der Heeden JF, Marinus J, Martinez-Martin P, Rodriguez-Blazquez C, Geraedts VJ, van Hilten JJ (2016) Postural instability and gait are associated with severity and prognosis of Parkinson disease. Neurology 86(24):2243–2250CrossRef

39.

de Lau LM, Verbaan D, Marinus J, van Hilten JJ (2014) Survival in Parkinson’s disease. Relation with motor and non-motor features. Parkinsonism Relat Disord 20(6):613–616CrossRef

40.

Hariz GM, Forsgren L (2011) Activities of daily living and quality of life in persons with newly diagnosed Parkinson’s disease according to subtype of disease, and in comparison to healthy controls. Acta Neurol Scand 123(1):20–27CrossRef

41.

Muslimovic D, Post B, Speelman JD, Schmand B, de Haan RJ (2008) Determinants of disability and quality of life in mild to moderate Parkinson disease. Neurology 70(23):2241–2247CrossRef

42.

Kadastik-Eerme L, Rosenthal M, Paju T, Muldmaa M, Taba P (2015) Health-related quality of life in Parkinson’s disease: a cross-sectional study focusing on non-motor symptoms. Health Qual Life Outcomes 13:83CrossRef

43.

Zhang LM, Zhang XP (2015) Investigation of urination disorder in Parkinson’s disease. Chin Med J 128(21):2906–2912CrossRef

44.

Visanji N, Marras C (2015) The relevance of pre-motor symptoms in Parkinson’s disease. Expert Rev Neurother 15(10):1205–1217CrossRef

45.

Erro R, Picillo M, Amboni M, Moccia M, Vitale C, Longo K et al (2015) Nonmotor predictors for levodopa requirement in de novo patients with Parkinson’s disease. Mov Disord 30(3):373–378CrossRef

46.

Sakakibara R, Shinotoh H, Uchiyama T, Yoshiyama M, Hattori T, Yamanishi T (2001) SPECT imaging of the dopamine transporter with [(123)I]-beta-CIT reveals marked decline of nigrostriatal dopaminergic function in Parkinson’s disease with urinary dysfunction. J Neurol Sci 187(1–2):55–59CrossRef

47.

Winge K, Friberg L, Werdelin L, Nielsen KK, Stimpel H (2005) Relationship between nigrostriatal dopaminergic degeneration, urinary symptoms, and bladder control in Parkinson’s disease. Eur J Neurol 12(11):842–850CrossRef

48.

Hattori T, Yasuda K, Kita K, Hirayama K (1992) Voiding dysfunction in Parkinson’s disease. Jpn J Psychiatry Neurol 46(1):181–186PubMed

49.

Lim SY, Fox SH, Lang AE (2009) Overview of the extranigral aspects of Parkinson disease. Arch Neurol 66(2):167–172CrossRef

50.

Djaldetti R, Lev N, Melamed E (2009) Lesions outside the CNS in Parkinson’s disease. Mov Disord 24(6):793–800CrossRef

51.

Khoo TK, Yarnall AJ, Duncan GW, Coleman S, O'Brien JT, Brooks DJ et al (2013) The spectrum of nonmotor symptoms in early Parkinson disease. Neurology 80(3):276–281CrossRef

52.

Pezzoli G, Cereda E (2013) Exposure to pesticides or solvents and risk of Parkinson disease. Neurology 80(22):2035–2041CrossRef

53.

Pan-Montojo F, Schwarz M, Winkler C, Arnhold M, O'Sullivan GA, Pal A et al (2012) Environmental toxins trigger PD-like progression via increased alpha-synuclein release from enteric neurons in mice. Sci Rep 2:898CrossRef

54.

Gokce Cokal B, Yurtdas M, Keskin Guler S, Gunes HN, Atac Ucar C, Aytac B et al (2017) Serum glutathione peroxidase, xanthine oxidase, and superoxide dismutase activities and malondialdehyde levels in patients with Parkinson’s disease. Neurol Sci 38(3):425–431CrossRef

55.

Ghaisas S, Maher J, Kanthasamy A (2016) Gut microbiome in health and disease: linking the microbiome-gut-brain axis and environmental factors in the pathogenesis of systemic and neurodegenerative diseases. Pharmacol Ther 158:52–62CrossRef

56.

Scheperjans F, Aho V, Pereira PA, Koskinen K, Paulin L, Pekkonen E et al (2015) Gut microbiota are related to Parkinson’s disease and clinical phenotype. Mov Disord 30(3):350–358CrossRef

57.

Forsyth CB, Shannon KM, Kordower JH, Voigt RM, Shaikh M, Jaglin JA et al (2011) Increased intestinal permeability correlates with sigmoid mucosa alpha-synuclein staining and endotoxin exposure markers in early Parkinson’s disease. PLoS One 6(12):e28032CrossRef

58.

Mayer EA, Tillisch K, Gupta A (2015) Gut/brain axis and the microbiota. J Clin Invest 125(3):926–938CrossRef

59.

Lema Tome CM, Tyson T, Rey NL, Grathwohl S, Britschgi M, Brundin P (2013) Inflammation and alpha-synuclein's prion-like behavior in Parkinson’s disease--is there a link? Mol Neurobiol 47(2):561–574CrossRef

60.

Felice VD, Quigley EM, Sullivan AM, O'Keeffe GW, O'Mahony SM (2016) Microbiota-gut-brain signalling in Parkinson’s disease: implications for non-motor symptoms. Parkinsonism Relat Disord 27:1–8CrossRef

61.

Grenham S, Clarke G, Cryan JF, Dinan TG (2011) Brain-gut-microbe communication in health and disease. Front Physiol 2:94CrossRef

62.

Li-Na Z, Deng C, Da X, Si-Han C, Hai-Jiao W, Ling L (2017) Mesencephalic astrocyte-derived neurotrophic factor and its role in nervous system disease. Neurol Sci 38(10):1741–1746CrossRef

63.

Neunlist M, Rolli-Derkinderen M, Latorre R, Van Landeghem L, Coron E, Derkinderen P et al (2014) Enteric glial cells: recent developments and future directions. Gastroenterology 147(6):1230–1237CrossRef

64.

Clairembault T, Leclair-Visonneau L, Neunlist M, Derkinderen P (2015) Enteric glial cells: new players in Parkinson’s disease? Mov Disord 30(4):494–498CrossRef

65.

McGeer PL, McGeer EG (2004) Inflammation and neurodegeneration in Parkinson’s disease. Parkinsonism Relat Disord 10(Suppl 1):S3–S7CrossRef

66.

Gao HM, Hong JS, Zhang W, Liu B (2003) Synergistic dopaminergic neurotoxicity of the pesticide rotenone and inflammogen lipopolysaccharide: relevance to the etiology of Parkinson’s disease. J Neurosci 23(4):1228–1236CrossRef

67.

Jenner P (2003) Oxidative stress in Parkinson’s disease. Ann Neurol 53(Suppl 3):S26–S36 discussion S-8CrossRef

68.

Leung L, Riutta T, Kotecha J, Rosser W (2011) Chronic constipation: an evidence-based review. J Am Board Fam Med 24(4):436–451CrossRef

69.

Doty RL (2009) The olfactory system and its disorders. Semin Neurol 29(1):74–81CrossRef

Titel: Analysis of the clinical features of early Parkinson’s disease with comparatively integrated intestinal function
verfasst von: Xiaoxue Guan
Yuchan Wang
Qun Li
Ming Wei
Lili Chen
Oumei Cheng
Publikationsdatum: 01.11.2018
Verlag: Springer Milan
Erschienen in: Neurological Sciences / Ausgabe 11/2018
Print ISSN: 1590-1874
Elektronische ISSN: 1590-3478
DOI: https://doi.org/10.1007/s10072-018-3502-3

Leitlinien kompakt für die Neurologie

Mit medbee Pocketcards sicher entscheiden.

^{Seit 2022 gehört die medbee GmbH zum Springer Medizin Verlag}

Kostenlos registrieren

Neu im Fachgebiet Neurologie

Akuter Schwindel: Wann lohnt sich eine MRT?

28.04.2024 Schwindel Nachrichten

Akuter Schwindel stellt oft eine diagnostische Herausforderung dar. Wie nützlich dabei eine MRT ist, hat eine Studie aus Finnland untersucht. Immerhin einer von sechs Patienten wurde mit akutem ischämischem Schlaganfall diagnostiziert.

Niedriger diastolischer Blutdruck erhöht Risiko für schwere kardiovaskuläre Komplikationen

25.04.2024 Hypotonie Nachrichten

Wenn unter einer medikamentösen Hochdrucktherapie der diastolische Blutdruck in den Keller geht, steigt das Risiko für schwere kardiovaskuläre Ereignisse: Darauf deutet eine Sekundäranalyse der SPRINT-Studie hin.

Frühe Alzheimertherapie lohnt sich

25.04.2024 AAN-Jahrestagung 2024 Nachrichten

Ist die Tau-Last noch gering, scheint der Vorteil von Lecanemab besonders groß zu sein. Und beginnen Erkrankte verzögert mit der Behandlung, erreichen sie nicht mehr die kognitive Leistung wie bei einem früheren Start. Darauf deuten neue Analysen der Phase-3-Studie Clarity AD.

Viel Bewegung in der Parkinsonforschung

25.04.2024 Parkinson-Krankheit Nachrichten

Neue arznei- und zellbasierte Ansätze, Frühdiagnose mit Bewegungssensoren, Rückenmarkstimulation gegen Gehblockaden – in der Parkinsonforschung tut sich einiges. Auf dem Deutschen Parkinsonkongress ging es auch viel um technische Innovationen.

Update Neurologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.

Newsletter bestellen

Springer Medizin

Abstract

Objective

Method

Results

Conclusions

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Weitere Artikel der Ausgabe 11/2018

Moyamoya complicated by thrombotic cerebrovascular accident in a Caucasian woman with collagenous colitis

Diastolic heart dysfunction is correlated with CTG repeat length in myotonic dystrophy type 1

Multiple sclerosis incidence in Tuscany from administrative data

Clinical presentation and natural history of infantile-onset ascending spastic paralysis from three families with an ALS2 founder variant

Clinical management of Duchenne muscular dystrophy: the state of the art